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Abstract: Objective: To create a mobile application able to help patients follow medical treatments
properly. Methods: We designed and developed a custom Android/iOS App to remind patients of the
pharmaceutical drugs to be taken, of the visits and exams to attend, and to detect their compliance
with their personal therapeutic plan. In this paper we describe the App development, UX/UI design,
Gamification. TuTOR is an Android and iOS application designed to remind patients of the drugs to be
taken, giving them all the information related to their therapeutic plans in a simple and non-invasive
way. Thanks to a dedicated back-office, specially designed to meet specific medical information needs,
the App can also help physicians detect their patients’ compliance with their treatments and modify
prescriptions in real time. The App also ensures a state-of-the-art approach to data security and privacy
protection. The main feature of TuTOR is the smart therapy assistant, which features dedicated alarms
to remind users of taking their prescription drugs. Thanks to the automatic synchronization with a
local database, the alert system works even without connection to the Internet. Particular attention
was paid during the App’s design process: we looked to create an intuitive interface to ensure absolute
ease of use, with state-of-the-art visual design aimed at maximizing user experience. Other relevant
features include the App’s ability to givevisual evidence of the most important drugs to be taken
and its note-taking feature, which gives patients the possibility to note down indications on why a
specific drug was skipped. The App also keeps track of upcoming medical exams, laboratory tests,
and visits on a devoted calendar. It also helps patients by listing therapy contacts, such as physicians’
phone numbers, and indicates all medical references by showing, for example, locations of relevant
clinics and pharmacies on a map. Thanks to specific visual progress indicators and an innovative
gamification approach, the App encourages users to faithfully follow therapy guidelines. With TuTOR,
assessing the therapy’s state of completion is quick and easy.Thanksto the privacy-by-design approach
used, all data managed by the system is compliant with the European Privacy Regulation and it is not
available to third parties. Expected results: A mobile App for medication adherence might increase
objectively and subjectively measured adherence.
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1. Introduction
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, mainly characterized
by chronic inflammation and persistent synovitis, which can lead to joint destruction and permanent
damage. The introduction of biological agents and, more recently, small oral molecules has changed
the scenario of pharmacologic treatment of RA and it has become a real revolution. These drugs
have innovative mechanisms of action, based on the inhibition of specific molecular or cellular targets
directly involved in disease pathogenesis [1–3].
Among small oral molecules, tofacitinib is an oral Janus kinase inhibitor approved for the treatment
of RA either as a monotherapy or in combination with conventional synthetic disease modifying
anti-rheumatic drug (csDMARDs). The efficacy and safety of tofacitinib 5 mg and 10 mg twice daily
administered as monotherapy or in combination with csDMARDs (mainly methotrexate) in patients
with active RA, have been demonstrated in two phase three studies [4,5]. One of most interesting
peculiarities of tofacitinib, when compared to the majority of the biological drugs used for the treatment
of RA, is the oral administration. However, while oral administration is undoubtedly considered an
advantage from a patients’ perspective, adherence to self-management and medication might raise
some concerns in treating physicians. This is particularly true in the management of chronic conditions
such as RA.
Notably, shifting medications, poly-pharmacy, and complexities of daily life are likely to contribute
to patients’ inability to deal adequately with their medical conditions, potentially leading to poor
disease control and/or management of co-morbidities. In RA, in particular, it is well known that
cardiovascular (CV) disease represents the most frequent cause of morbidity and mortality, accounting
for 39%–50% of deaths in this particular subgroup of subjects [6]. Nonetheless, up to 50% of RA
patients stop taking medication for CV comorbidities during the first year of prescription [7–10].
Besides, a proper adherence to self-management and medication can be even more challenging in
specific sub-populations of RA patients, such as the elderly because of the concurrent use of multiple
medications and reduced awareness of their medical condition.
Novel strategies are warranted to better monitor and address the needs of chronically ill patients
that are self-managing their often complex treatment. In this context, mobile information technology
may offer new solutions to better meet these needs. In fact, these technologieshave already been applied
for other diseases and has demonstrated to substantially improve pharmaceutical adherence [11,12].
We aim to develop a mobile application to support the management of RA patients treated with
tofacitinib in order to improve their therapy adherence: the TuTOR (Tailoring Tofacitinib Oral therapy
in Rheumatoid arthritis) mobile App. The project is divided in two main phases. The first phase
(Phase I) includes the TuTOR mobile App design and development. A second phase (Phase II) is based
on the TuTOR mobile App clinical validation. In phase II the effect on participants’ reported adherence
to medication, laboratory parameters, and clinical follow-up will be evaluated. Adherence to therapy
will be investigated through objective information acquired from the logged interaction protocols
and users’ subjective assessments and quality of life questionnaires. In addition, the influence on
affinity for technology will be evaluated at baseline in order to determine if particular subgroups of
RA patients will benefit more from the use of the mobile App.
Herewith, we aim to describe the study protocol and the milestones of Phase I of the TuTOR
project which led to the App development.
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2. Methods
2.1. Phase I: TuTOR Mobile App Design and Development
We designed and developed a custom Android/iOS App to remind patients of the pharmaceutical
drugs to be taken, of the visits and exams to attend, and to detect their compliance with their personal
therapeutic plan. All of the materials will be available in English and Italian (the native language of
the participants). More information on the technical aspects of the TuTOR developing architecture is
provided as Supplementary Material.
Taking medication accurately means better therapy results. Drug therapies with complex intake
timetables are difficult for patients to follow and measuring the medical effectiveness of a therapy with
a discontinuous or inaccurate application can lead to unreliable results: this is why the TuTOR App
idea took shape. TuTOR is an Android and iOS application designed to remind patients of the drugs to
be taken, giving them all the information related to their therapeutic plans in a simple and non-invasive
way. The App also ensures a state-of-the-art approach to data security and privacy protection.
2.1.1. Not Just A Reminder: Smart Therapy Assistant
The main feature of TuTOR is the smart therapy assistant, which features dedicated alarms to
remind users of taking their prescription drugs. Thanks to the automatic synchronization with a
local database, the alert system works even without internet access. This ensures that alerts work in
all conditions, a crucial element to help patients never forget their medications. Particular attention
was paid during the App’s design process, particularly focusedto create an intuitive interface to
ensure absolute ease of use, with state-of-the-art visual design aimed at maximizing user experience.
Other relevant features include the App’s ability to give visual evidence of the most important drugs
to be taken and its note-taking feature, which gives patients the possibility to note down indications on
why a specific drug was skipped. The App also keeps track of upcoming medical exams, laboratory
tests, and visits on a dedicated calendar. It also helps patients by listing therapy contacts, such as
physicians’ phone numbers, and indicates all medical references by showing, for example, locations
of relevant clinics and pharmacies on a map. Thanks to specific visual progress indicators and an
innovative gamification approach, the App encourages users to faithfully follow therapy guidelines.
With TuTOR, assessing the therapy’s state of completion is quick and easy.
2.1.2. Medical Plan
In this form, the patient will find all listed medications that they are currently taking. Information
provided will include the name of the medication, the number of intakes per day, and corresponding
doses. The patient will not be able to change the list of medications, only the investigator of the study
will be provided with the code to change the “Medical Plan” settings. The patients will have to check
the boxes each day when taking every medication suggested by the TuTOR mobile App with the
possibility to recover a wrong information if given a wrong input.
Figure 1 shows the medical plan in the TuTOR mobile App.
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Figure 1. Medical plan in the TuTOR mobile App.
2.1.3. Clinical Follow-up
In this form, the patient will find all planned follow-up clinical appointments according to
the treating clinician indications. Information provided will include follow-up visits (date, time,
location, and name of the reference Doctor of the center), specialist appointments (date, time, location,
and name of the Specialist Doctor), instrumental testing (date, time, and location), and laboratory
testing (date, time, and location). The patient will not be able to change the planned follow-up list,
only the investigator of the study will be provided with the code to change the “Clinical Follow-up”
settings. The patients will have to check the boxes for each follow-up visit performed suggested by
the TuTOR mobile App with the possibility to recover a wrong information if given a wrong input.
Figure 2 sho s the clinical follow-up plan in the TuTOR mobile App.
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Figure 2. Clinical follow-up plan in the TuTOR mobile App.
2.2. Phase II: Validation of the TuTOR App
2.2.1. Clinical Validation of TuTOR Mobile App Protocol
This study will include a total of 20 RA patients that will begin treatment with tofacitinib jointly
to the use of the TuTOR mobile App, developed to improve adherence to self-management, clinical
follow-up, and medication monitoring. Patients will be followed-up for 6 months, with personal
questionnaires at baseline and every 3 months. Clinical and laboratory follow-up will be evaluated by
the treating clinician according to patient’s comorbidities and specific needs.
At baseline, with the help of certified questionnaires (drafted in the native language of the
participants), technologyliteracy and digital health literacy will be evaluated in order to assess the
affinity for technology and its influence on the outcomes of the study. Adherence to therapy will
be investigated from one hand through objective information acquired from the logged interaction
protocols. From the other hand, this study will use certified quality of life questionnaires and adherence
to therapy questionnaires in order to assess qualitative indicators and subjective feedbacks from the
patients and their experience in using the TuTOR App.
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The recruited patients will then receive a personal learning-by-doing tutorial session and
introduction to the TuTOR mobile App, installed on a tablet or smartphone. The participants
will be familiarized with the functions of the application (i.e., confirming medication intake and
recording follow-up visits and clinical appointments) and how to recover if a wrong input had
been made.
The study will be conducted using a crossover design with three sequences: initial phase
(training and baseline assessment), interventional phase (3 months of therapy using the App system),
and comparative phase (3 months of treatment using a paper-diary). Users will experience the
interventional and comparative phases alternately. Figure 3 shows the timeline of the research protocol
of the study.
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2.2.2. Patients Characteristics
Inclusion Criteria
Individuals aged 18 years or older who meet the 2010 ACR and EULAR classification criteria for
RA [13] with active diseasedefined as having four or more tender or painful joints on motion and four
or more swollen joints (based on a 28 joint count) at baseline despite treatment with methotrexate
(15–25 mg per week), high-sensitivity C-reactive protein of≥3 mg/L, and class I–III functional capacity as
classified by the ACR 1991 revised criteria for global functioning status in RA [14]. Patients are required
to discontinue all csDMARDs, other than methotrexate, for at least 4 weeks or five half-lives, whichever
was longer, before baseline, but could continue to receive stable non-steroidal anti-inflammatory drugs,
analgesics, or oral corticosteroids, or a combination, throughout the study. Patients who had responded
inadequately or had an adverse event secondary to treatment with a biological DMARD (bDMARD)
could be included after having discontinued the bDMARD for a minimum period of time depending on
the specific agent (i.e., rituximab or other selective B lymphocyte depleting agents 52 weeks; abatacept,
certolizumab pegol, and tocilizumab 12 weeks; golimumab 10 weeks; infliximab 8 weeks; and anakinra
and etanercept 4 weeks).
Exclusion Criteria
Contraindications for any study treatment; a history of infections requiring treatment within
2 weeks, or any admission to hospital within the 6 months before the beginning of the study;
had exclusionary morbidities, HIV, hepatitis B or C; inadequately treated or undocumented treatment
for tuberculosis; one episode of disseminated herpes zoster or herpes simplex; any clinically significant
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laboratory abnormalities; ongoing pregnancy. Exclusion criteria include also patients who had
previously received tofacitinib, or live attenuated vaccines other than the herpes zoster vaccine (within
6 weeks before study initiationor planned within 6 weeks after discontinuation of study treatment).
2.3. Data Analysis
2.3.1. Objective Indicators for Therapy Adherence and Clinical Follow-up
Confirmation rates of medication intake and the number of follow-up records in mobile App
and in the paper-diary will be analyzed. More in detail, the patient will have the option to choose
why they are not taking the medication: (a) forgetfulness, (b) intolerance/allergy reaction, (c) scarce
efficacy. In order to be able to compare the outcomes of the interventions, a target–performance
comparisonwill be performed. For medication, the target is defined as the number of medications each
participant has to take each day multiplied by the days they actually used the system or the diary.
The variable “absolute performance” is defined as the actual number of confirmations made by the
patient that they took the medication. Having to take >1 unit (i.e., >1 pill) of a single medication at the
same point in time or on the same day is considered as one medication intake (“all or none”) as the
application cannot register whether participants only took a subset of a particular medication. The rate
of adherence to confirm medication then will be the ratio of performance and target multiplied by
100 to obtain a percentage value. Assessing adherence for clinical follow-up recording isperformed
similarly, as participants have a tailored follow-up depending on the single comorbidities and different
follow-up visits. Every specialist visit is considered as one follow-up confirmation, as well as every
laboratory monitoring and instrumental tests. Similarly, to medication, the rate of adherence to clinical
follow-up will be the ratio of performance and target multiplied by 100 to obtain a percentage value.
2.3.2. Back-Office
The TuTOR App features a complete dashboard to allow physicians to keep their patients’ therapies
under control, monitoring their adherence toprescriptions (Figure 4). In TuTOR, physicians also have
all patients’ relevant medical information under control. The back-office is designed to keeptrack, visit
after visit, of drugs, dosages, times of intake, and previous therapies. All data is synchronized in real
time on patients’smartphones, giving physicians the possibility to modify therapies in a timely manner.
Thanks to the privacy-by-design approach used, all data managed by the system is compliant with the
European Privacy Regulation and it is not available to third parties.
2.3.3. Subjective Indicators for Therapy Adherence and Clinical Follow-up
Technical knowledge and experience are assessed using an adapted version of the computer
literacy scale (CLS) [15]. Subjective adherence are determined by the A14-scale, which contains 14 items
that ask participants to report on a five-point scale, ranging from “never” (0) to “very often” (4), their
behavior with respect to medication adherence and the degree to which various barriers to adherence
apply to them [16]. Based on the A14-scale, values < 50 are regarded as non-adherent and values
between 50 and 56 as adherent (sums ranging between 0 and 56).
A questionnaire investigating quality of life and adherence to therapy (supplement A) will also be
implemented in the follow-up visits to determine the influence of the TuTOR App in the aspects of
daily life and overall patients’ satisfaction.
2.3.4. Statistical Analysis Plan
Data will be analyzed using SPSS statistics software version SPSS 26.0 (IBM, Armonk, New York).
A multifactorial analysis of variance (ANOVA) with repetitions for the different factor levels of the
response variables with a significance level of 0.05 was will be conducted. Significant findings will be
additionally analyzed by post hoc analysis and Bonferroni correction to minimize the Type-I error rate
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because of multiple paired comparisons of mean values. Multivariate logistic regression analysis will
be performed to identify significant independent factors.
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